| abstract |
Provide melanin-concentrating hormone receptor ligands (especially substituted 2- (4-benzyl-piperazin-1-ylmethyl) -1H-benzimidazole analogs) that can modulate MCH activity. Such ligands can be used to modulate MCH binding to MCH receptors in vivo or in vitro, particularly treating various human, pet and livestock metabolic diseases, eating disorders and sexual disorders. To help. Along with methods using such ligands to detect MCH receptors (eg, receptor localization studies), pharmaceutical compositions and methods for treating such diseases are provided. |